Turn this list into pipeline.
Cell & Gene Therapy Companies in the UK: 66 Active Firms (2026)
Cell and gene therapy companies develop advanced therapies using modified cells, genes or tissue engineering within the UK ATMP framework.
Buying centres tend to sit in translational science, clinical development, GMP manufacturing and analytical quality control, rather than in general corporate procurement. Customers are usually other therapy developers, manufacturers or clinical sponsors that need specialised capacity, manufacturing capability, validated assays or platform support inside the UK ATMP environment. Engagements are usually high-touch and technical: a development collaboration, a manufacturing or import pathway, or a service contract tied to release testing, process development or trial supply. The buying cycle tends to involve scientific, clinical, quality and regulatory teams together, with MHRA expectations shaping the evidence package well before commercial launch.
Read more
At UK level, the cohort comprises 66 actively trading companies, of which 5 report turnover above £5M and 13 were incorporated since 2022. Employment is also concentrated, with total reported headcount of 588 across the firms that disclose staff numbers. The shape is therefore a specialist company universe: therapy developers, manufacturing-service providers, analytical-service teams and enabling-technology businesses, rather than a broad horizontal technology category. A relatively small revenue-scaled layer sits above a younger group still moving through technical, clinical and regulatory milestones.
Cell and gene therapy work falls within the UK ATMP regime. The MHRA is the competent authority for medicinal products and for UK manufacturers or importers of ATMPs; clinical-trial applications go to the MHRA, marketed therapies need authorisation, and manufacturers need a manufacturer’s licence. The regime distinguishes gene therapy medicinal products, somatic cell therapy medicinal products and tissue-engineered products. Where human tissues or cells are used as starting materials, the Human Tissue Authority and Human Fertilisation and Embryology Authority may also be relevant before medicines legislation applies. Market structure follows from that: evidence generation, quality systems and licensed capacity are part of the commercial model, not just compliance overhead.
Commercial progression appears likely to remain uneven. Therapy developers tend to need long technical validation cycles, while service and enabling-technology suppliers can reach revenue earlier through manufacturing, analytics or platform work. Scale-up scarcity is likely to persist because licensing, quality systems and clinical evidence requirements raise the cost of moving from specialist research capability into repeatable commercial delivery. The cohort may also see more partnership and acquisition activity as larger life-science buyers look for capacity, intellectual property or process expertise. Near-term differentiation is likely to rest less on broad discovery claims and more on manufacturability, trial readiness and regulatory execution.
66
Active firms
2026
5
Over £5M turnover
Companies crossing threshold
13
Incorporated since 2022
Newer registrations
Key facts
About 7% of the trading cohort reports turnover above £5M (5 of 66 firms) — the rest sits below that revenue band.
19% of the cohort was incorporated since 2022 (13 firms), so a sizeable share is in its first few filing cycles.
Cell and gene therapies generally fall within the UK ATMP framework, covering gene therapy medicinal products, somatic cell therapy medicinal products and tissue engineered products under the Human Medicines Regulations 2012.
The MHRA handles ATMP clinical-trial applications, marketing authorisations and manufacturer licensing; the Human Tissue Authority and Human Fertilisation and Embryology Authority may also be relevant where human tissues and cells are starting materials.
UK ATMP investment was £1.7 billion in 2022, £0.77 billion in 2023 and £0.97 billion in 2024, leaving the market below the 2022 peak.
UK ATMP GMP manufacturing facility space reached 51,862 m² in 2024.
The UK had 187 ongoing advanced therapy clinical trials in 2024, up 7% year on year, with Phase I trials rising from 24 to 41.
Top UK Cell & Gene Therapy companies
ADVENT BIOSERVICES LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides contract development and manufacturing services for cell and gene therapies. Operates GMP-compliant facilities for cell therapy production, process development, quality control testing, and…
Serves biotechnology and pharmaceutical companies developing cell and gene therapies, including organisations needing GMP production scale-up, process development, QC support and ultra-cold storage…
Financial Health
DistressedDistressed · -54% CAGR over 4y
Location
Provides contract development and manufacturing services for advanced therapy products including gene therapies, vaccines and immunotherapies. Offers process development, formulation, analytics and…
Serves life-science innovators and advanced therapy developers, including biotech and pharma teams working on gene therapies, immunotherapies, oncolytics and vaccines from research through…
Location
Cytera Cellworks Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides contract development and manufacturing services for regenerative medicine. Uses automated iDEM technology to produce cell therapies at scale, supporting cell culture, process and analytical…
Serves clinical-stage regenerative medicine and cell therapy biotech companies developing therapies for areas such as brain, eye, bone, hearing and corneal conditions, particularly teams needing…
Financial Health
HealthyHealthy · Hiring · 29% CAGR over 4y
Location
Develops gene therapies for inherited and degenerative eye diseases. Conducts research and clinical trials using adeno-associated virus (AAV) gene therapy to treat conditions such as X‑linked…
Serves patients with inherited and age-related retinal diseases, plus healthcare providers and clinical trial partners involved in ophthalmic gene therapy for XLRP, dry AMD and cone rod dystrophy.
Location
Develops gene therapies for ophthalmic diseases, focusing on inherited and degenerative retinal disorders. Conducts research and clinical trials using AAV‑based gene therapy targeting conditions…
Serves patients and caregivers affected by inherited and age-related retinal diseases, alongside ophthalmology healthcare providers and clinical trial participants for XLRP, dry AMD and cone rod…
Location
Develops regenerative macrophage cell therapies for the treatment of inflammatory and fibrotic diseases. Conducts research, development and manufacturing of engineered macrophage-based therapeutics,…
Targets patients with inflammatory and fibrotic diseases, particularly liver cirrhosis, via specialist clinicians, hospitals, trial sites and healthcare systems involved in advanced liver disease…
Location
SAFI BIOSOLUTIONS UK LIMITED
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops and manufactures human red blood cells derived from adult stem cells for use as transfusion therapies. Conducts biotechnology research and scalable biomanufacturing to produce clinical‑grade…
Targets healthcare providers, hospitals, blood transfusion services and government or defence agencies serving civilian care, chronic transfusion patients, military settings and emergency stockpiling.
Financial Health
HealthyHealthy · Hiring · 11% CAGR over 3y
Location
Trajectory
5y · 2020–NowDevelops cancer immunotherapies based on natural killer (NK) cells and small‑molecule compounds. Uses stem cell‑derived and engineered NK cells to create therapeutic candidates targeting…
Targets the oncology market, with future customers and stakeholders including healthcare providers, cancer patients with haematological or solid tumours, and life sciences investors.
Financial Health
Insufficient historyInsufficient history
Location
Swarm Oncology Limited
Trajectory
2y · 2023–NowFinancial sub-scores
Computed from 2 filingsDevelops personalised T cell therapies for cancer treatment. Uses a platform combining in vivo priming and ex vivo optimisation to create targeted cell therapies designed to recognise…
Serves oncology healthcare and life sciences organisations, including hospitals, research collaborators and commercial partners, with engagement also aimed at specialist investors in T cell therapy.
Financial Health
WeakWeak · Hiring · 100% CAGR over 1y
Location
Immunokey Ltd
Trajectory
1y · 2025–NowDevelops cell therapy technologies for cancer treatment, focusing on CAR T‑cell approaches for solid tumours. Conducts research and development of platform technologies and therapeutic candidates,…
Serves cancer patients and oncology care providers, with an initial focus on ovarian cancer and other solid cancer cases where patients have limited treatment options.
Financial Health
Insufficient historyInsufficient history
Location
SYNGENSYS LIMITED
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops synthetic gene promoters and computational design tools to control gene expression for gene therapy, cell therapy and biologics manufacturing. Provides promoter libraries, tissue‑targeted…
Serves biotech and pharmaceutical organisations developing gene and cell therapies, biologics and biomanufacturing platforms, including teams working with tissue-targeted expression, CHO production…
Financial Health
HealthyHealthy · -59% CAGR over 3y
Location
Develops gene therapies and delivery technologies targeting neurodegenerative disorders. Conducts research and clinical development of RNA‑silencing and other gene therapy treatments for conditions…
Serves patients and caregivers affected by neurodegenerative and retinal diseases, alongside clinical trial investigators and biopharma partners focused on FTD, ALS, Alzheimer’s/tauopathies and…
Location
Entos AI Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops genetic medicines and nucleic acid therapies using the Fusogenix PLV delivery platform and fusion protein technology. Focuses on targeted delivery systems that enable precise biodistribution…
Serves biopharma partners, government stakeholders and investors involved in genetic medicine, while ultimately targeting patients and families affected by diseases with unmet clinical needs.
Financial Health
StrongStrong · Growing · 0% CAGR over 4y
Location
Sterling Bio Machines Ltd
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops automated bioreactor systems for cell therapy manufacturing, particularly iPSC and other allogeneic cell processes. Technology integrates sensors, control software and perfusion modules to…
Serves biotech and pharma cell therapy developers, CDMOs, process development teams, academic labs and translational researchers scaling iPSC-based and allogeneic therapies from R&D toward clinical…
Financial Health
StrongStrong · Hiring · 150% CAGR over 1y
Location
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops software platforms for managing cell and gene therapy supply chains. Provides systems that track patients, materials, manufacturing, and logistics across clinical trials and commercial…
Serves cell and gene therapy developers and other advanced therapy organisations, from clinical trial teams to commercial supply chain stakeholders, including healthcare providers, logistics…
Financial Health
StableStable · -68% CAGR over 4y
Location
Develops oncolytic immunotherapies for colorectal cancer. Uses its T‑SIGn platform to create systemically delivered viruses that target tumours and deliver immune‑modulating genes, advancing drug…
Serves people living with colorectal cancer, particularly patients with mismatch repair-proficient locally advanced rectal cancer, alongside clinical trial participants and patient communities.
Location
NUNABIO LIMITED
Trajectory
5y · 2023–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies synthetic DNA using cell‑free production technology. Provides contract development and manufacturing services and distributed micro‑foundry systems for producing DNA constructs…
Serves biotech and pharmaceutical researchers, therapy and vaccine developers, advanced materials manufacturers, and government partners from discovery through clinical and commercial development.
Financial Health
StrongStrong · Growing, Hiring · 22% CAGR over 3y
Location
Entos Pharmaceuticals U.K.
Develops genetic medicines and nucleic acid therapies using its Fusogenix delivery platform. Conducts research and development of targeted gene delivery systems and therapeutic candidates, and…
Serves biopharmaceutical partners and public-sector funders involved in genetic medicine, with patients and families affected by diseases as the end beneficiaries.
Location
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops oncolytic virus therapies for cancer treatment. Uses genetically modified adenoviruses and a multi‑modality delivery system to target and destroy tumour cells while stimulating immune…
Targets the oncology healthcare market, with therapies intended for cancer patients, particularly those with solid tumours, and stakeholders involved in clinical development and cancer treatment.
Financial Health
WeakWeak · 0% CAGR over 2y
Location
Biovault Technical Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProcesses, stores and releases stem cells and human tissue products for medical use. Provides cellular therapy processing, biobanking, cord blood and tissue storage, and handling of allografts, along…
Serves public-sector NHS organisations, private clinics, and healthcare or life-science teams working with cellular therapies, allografts, biobanking and related regulated projects.
Financial Health
HealthyHealthy · -14% CAGR over 4y
Location
Biovault Scientific Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides processing, storage and release of stem cells and human tissue products for cellular therapies and allografts. Operates biobanking facilities and offers cord blood and tissue storage,…
Serves NHS organisations, private clinics, and healthcare or life-science partners involved in cellular therapies, stem cells, human tissue, allografts, biobanking, and related clinical programmes.
Financial Health
StableStable · -5% CAGR over 4y
Location
Develops engineered cell-based therapeutic platforms using genome editing and synthetic biology. Programs immune-derived cells to deliver targeted therapeutic payloads such as cytokines, antibodies…
Targets healthcare markets focused on patients with complex diseases, particularly cancer and autoimmune conditions.
Location
Wyvern Pharma Ltd
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsDevelops gene therapy technologies using plasmid vectors delivered via viral and non‑viral methods to upregulate or downregulate disease‑related genes, targeting conditions including autoimmune,…
Targets large patient populations with serious unmet treatment needs, particularly in autoimmune, neurological, metabolic and infectious diseases, and cancer.
Financial Health
DistressedDistressed · -15% CAGR over 2y
Location
Trajectory
2y · 2021–NowFinancial sub-scores
Computed from 2 filingsDevelops targeted cancer immunotherapies, including a universal CAR T cell platform and antibody-based treatments targeting the nfP2X7 receptor. Conducts research and development of therapies for…
Targets the oncology healthcare market, with therapies intended for cancer patients suffering from a wide range of liquid and solid tumours worldwide.
Financial Health
StableStable · 0% CAGR over 1y
Location
Develops targeted cancer immunotherapies, including a universal CAR T platform (BRiDGECAR) that combines nfP2X7‑targeted CAR T cells with antibodies. Conducts research and development of treatments…
Targets oncology healthcare markets, ultimately serving cancer patients with liquid and solid tumours worldwide. The site also addresses life sciences investors and eligible existing shareholders.
Location
LIR THERAPEUTICS LIMITED
Trajectory
1y · 2025–NowDevelops engineered viral vectors for gene therapy using AI modelling and laboratory assays. Focuses on designing adeno-associated virus (AAV) capsids to improve tissue targeting, reduce dosage…
Targets B2B biopharma companies, gene therapy developers and research teams working with AAV or other viral-vector platforms, especially those seeking technical collaborators for preclinical…
Financial Health
Insufficient historyInsufficient history
Location
Develops synthetic biology technology to reprogram induced pluripotent stem cells into specific human cell types. Supplies iPSC‑derived cells, disease model cells and CRISPR‑ready cells, and provides…
Serves life sciences researchers in biotech, pharmaceutical and academic labs, especially teams working on drug discovery, disease modelling, CRISPR screening and cell therapy development.
Location
Scarlet Therapeutics Limited
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops red blood cell‑based therapeutics using engineered cells that carry therapeutic proteins. Operates a biotechnology platform to produce therapeutic red blood cells from cell lines for…
Financial Health
StableStable
Location
SISTEMIC SCOTLAND LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops microRNA‑based molecular diagnostic assays and analytical services for cell and gene therapy research and manufacturing. Provides tests for residual pluripotent stem cells, mycoplasma…
Serves B2B customers in pharmaceutical, biotechnology, and cell and gene therapy research, development, and manufacturing, including teams involved in cell therapy characterisation, quality control,…
Financial Health
StableStable · -5% CAGR over 4y
Location
BIOGRAD LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsProvides clinical trial services, biobanking, and human tissue sample collection and storage. Develops biomanufacturing capabilities for advanced cell therapies, including stem cell and CAR‑T…
Serves private and NHS hospitals, UK and international biotech and pharmaceutical companies, academic researchers, and government bodies.
Financial Health
StrongStrong · Growing, Hiring · 29% CAGR over 4y
Location
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops gene therapy treatments for ophthalmic diseases. Conducts pre‑clinical research and builds a pipeline of bi‑functional gene therapies designed to deliver genetic instructions targeting…
Serves healthcare markets through ophthalmology-focused gene therapy, targeting patients with common eye diseases such as AMD and engaging investors and potential biopharma or research partners for…
Financial Health
StrongStrong · Hiring · 5% CAGR over 3y
Location
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops immunotherapy technologies aimed at improving how immune cells recognise and attack disease targets. Focuses on research into T‑cell interactions and technologies designed to enhance the…
Targets biopharmaceutical and cell therapy organisations developing CAR-T and other immunotherapies, alongside research collaborators and partners in immune-cell targeting.
Financial Health
DistressedDistressed · 0% CAGR over 1y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops cell analysis technology for bioprocessing and cell therapy manufacturing. Its AuraCyt‑based Celledonia platform measures intrinsic cell properties without labelling to generate predictive…
Serves biopharmaceutical and cell therapy organisations, particularly bioprocessing and cell line development teams working on monoclonal antibodies, viral vectors, and allogeneic or autologous cell…
Financial Health
StrongStrong · Hiring · 32% CAGR over 4y
Location
GENE WEAVER LTD
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops RNA-based genome engineering technology for precise genetic modification. Designs programmable molecular systems that recognise DNA, join strands and synthesise sequences to insert large…
Serves B2B life sciences customers, including genetic medicine and cell/gene therapy developers, industrial biotech teams working with microbes or plants, and organisations exploring non-CRISPR gene…
Financial Health
DistressedDistressed · 0% CAGR over 1y
Location
Bitrobius Genetics Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops gene therapy technology for treating genetic diseases. Its Gentrafix platform uses replicating plasmid DNA designed to spread between cells and deliver functional gene copies, enabling…
Targets patients affected by genetic diseases with no effective treatments or therapies that are costly, limited in scope, or short-duration; also addresses life-science investors and gene therapy…
Financial Health
StrongStrong
Location
AXOVIA THERAPEUTICS LTD
Trajectory
3y · 2024–NowFinancial sub-scores
Computed from 3 filingsDevelops gene therapies for genetic ciliopathy disorders including Bardet-Biedl syndrome. Its lead programme uses AAV9 viral vectors to deliver functional BBS1 genes to tissues, aiming to treat…
Targets patients with ciliopathies, especially Bardet-Biedl Syndrome caused by BBS1 mutations, along with caregivers and specialist healthcare communities involved in genetic obesity and blindness.
Financial Health
HealthyHealthy · Hiring · 100% CAGR over 2y
Location
Exogene Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops machine‑learning and generative AI tools to discover and engineer T‑cell receptors (TCRs) for cancer immunotherapies. Uses computational models to analyse TCR sequence space and identify…
Financial Health
StableStable · Hiring · 11% CAGR over 4y
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops biotechnology treatments for hair loss, including a follicle banking service that stores hair follicles for future use and cell‑based therapies that culture follicle cells for injection into…
Targets hair transplant clinicians and clinics, clinical partners, and male and female patients with androgenic alopecia seeking hair rejuvenation pathways; also addresses investors in biotech…
Financial Health
HealthyHealthy · Growing, Hiring · 4% CAGR over 4y
Location
BIOLOGIC TECHNOLOGIES LIMITED
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops laboratory manufacturing systems for biologics development and production. Its Qudos platform provides controlled processing, data capture and scalable workflows for applications such as…
Serves biotech and pharmaceutical R&D and manufacturing teams developing advanced biologics, including cell line development, fermentation studies and mRNA therapy programmes, from early labs to…
Financial Health
HealthyHealthy · Hiring · 6% CAGR over 4y
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops lipid nanoparticle (LNP) targeting technologies for drug delivery. Its NanoPilot platform engineers LNPs to deliver therapeutics to specific cell types while reducing off‑target liver…
Serves pharmaceutical and biotech companies developing LNP-based therapeutics, including teams seeking licensing opportunities for targeted drug-delivery technologies.
Financial Health
StableStable · -10% CAGR over 4y
Location
Virogen Ltd
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops oncolytic virotherapy drugs using engineered viruses to treat cancer and other serious diseases, focusing on therapies intended to target and destroy tumour cells through viral mechanisms.
Financial Health
StrongStrong
Location
NUNTIUS THERAPEUTICS LIMITED
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops mRNA-based genetic medicines using proprietary nanocarrier delivery systems, machine learning models, and nucleic acid engineering. Conducts drug discovery and development of therapies…
Targets pharmaceutical and biotech partners and, ultimately, patients with life-threatening diseases, particularly in cancer, lung disease and neurodegenerative disease treatment markets.
Financial Health
StableStable · Hiring · 40% CAGR over 3y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops regenerative medicine therapies including cell-based treatments designed to promote vascular regeneration and tissue repair. Conducts biomedical research and development focused on…
Financial Health
HealthyHealthy · Hiring · 46% CAGR over 4y
Location
DELIVER BIOSCIENCES LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops nanoparticle-based delivery systems for in vivo cell and gene therapies, enabling targeted transport of genetic payloads such as CRISPR tools to reprogram patient cells. Technology aimed at…
Serves healthcare and life sciences customers developing advanced therapies, particularly cell and gene therapy and cancer immunotherapy programmes. Targets biotech and pharmaceutical R&D teams…
Financial Health
StableStable · -54% CAGR over 5y
Location
Coding Bio Limited
Trajectory
4y · 2021–NowFinancial sub-scores
Computed from 4 filingsDevelops modular immunotherapies for cancer and other diseases using high‑throughput cell screening and machine learning. Generates and tests large libraries of engineered proteins, such as CAR and…
Serves biopharmaceutical and biotech partners developing cancer immunotherapies, especially teams working on modular protein, CAR or BiTE therapies seeking preclinical candidates for clinical…
Financial Health
StrongStrong · Hiring · 104% CAGR over 3y
Location
Develops T cell receptor-based immunotherapies for cancer. Uses a proprietary platform and humanised mouse models to identify and generate human T cell receptors that enable drugs designed to direct…
Targets oncology markets, ultimately serving cancer patients and healthcare providers treating tumours; also addresses biopharmaceutical investors and scientific stakeholders in TCR-based…
Location
UNCHAINED LABS UK MALVERN LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and sells laboratory instruments, automation systems and consumables for life science research. Products measure and analyse proteins, nucleic acids and viral vectors, supporting sample…
Serves life science researchers and biopharma R&D teams working on biologics, gene therapy, cell therapy, nanoparticles, exosomes and genomics, including lab and process development groups.
Financial Health
WeakWeak · -38% CAGR over 4y
Location
Trajectory
3y · 2024–NowFinancial sub-scores
Computed from 3 filingsDevelops biotechnology for targeted gene delivery, using artificial intelligence to design and optimise systems that transport genetic material into specific cell types for research and potential…
Financial Health
WeakWeak · Hiring · 58% CAGR over 2y
Location
UNCHAINED LABS LTD
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsDevelops and manufactures laboratory instruments and automation systems for biologics, gene therapy and nanoparticle research. Products measure protein and nucleic acid concentration, particle size,…
Sells to biologics, gene therapy, cell therapy, genomics and nanoparticle researchers in biotech, pharmaceutical and academic labs, including teams working on antibodies, viral vectors, LNPs,…
Financial Health
DistressedDistressed · -37% CAGR over 3y
Location
NEUROCHASE HOLDINGS LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops drug delivery technologies for the central nervous system, including convection‑enhanced delivery devices for gene and other therapeutics. Provides consultancy, training, and pre‑clinical…
Serves biotech and pharmaceutical companies, CROs and clinical research teams developing neurological disease therapies, from pre-clinical studies through clinical trials.
Financial Health
HealthyHealthy · 0% CAGR over 2y
Location
Unlock all 66 leads
Showing 50 of 66 — +16 more with verified decision-maker contacts, live data, and CRM sync.
How UK Cell & Gene Therapy companies work and how to sell to them
What they do
Cell and gene therapy companies usually make money in one of three ways: advancing owned therapeutic assets, selling specialist development or manufacturing services, or licensing enabling technology into other ATMP programmes. Therapy developers tend to be milestone-led businesses, with revenue arriving through collaborations, trial sponsorship arrangements or later-stage licensing rather than ordinary product sales. Service providers are more commercial from the outset, pricing around process development, GMP manufacturing slots, import or release activities and validated analytical work. Engagements are rarely self-serve; they are scoped as technical work packages with quality, regulatory and clinical dependencies.
Who they sell to
Most buyers are themselves therapy developers, clinical sponsors, specialist manufacturers or platform teams that need UK ATMP capability they cannot build quickly in-house. The first conversation is often with a chief scientific officer, head of process development, clinical operations lead or quality director, while finance, legal and procurement join once capacity, liability and regulatory evidence are being committed. Contract size tends to follow risk rather than seat count: a release assay, tech-transfer package or manufacturing campaign is assessed on patient, trial and batch consequences. Direct technical selling is common, with RFPs appearing for larger outsourced manufacturing or trial-supply work.
What they buy
Most cell and gene therapy firms tend to spend on systems and suppliers that protect traceability, quality and evidence. Relevant categories include electronic quality management, document control, laboratory information management, sample tracking, inventory, clinical operations tooling, validation support, cyber security and secure research computing. Manufacturing-led firms also buy cleanroom services, specialist facilities support, cold-chain logistics, GMP consumables, equipment calibration and maintenance, and analytical instrumentation support. Earlier-stage therapy developers tend to need regulatory consulting, biostatistics, trial operations, grant and partnership support, patent advice, finance support and specialist recruitment for clinical, quality, regulatory, process-development and analytical roles.
Why and how to sell to them
Buying intent often appears when a programme moves from research into GMP work, an assay has to be validated, a clinical-trial package is being prepared, or a manufacturing route needs to be insourced, outsourced or transferred. Other triggers include a senior hire in quality or regulatory affairs, a new clinical sponsor relationship, a funding event, a licensing deal, or visible recruitment for manufacturing and analytical roles. Sellers usually need to lead with risk reduction rather than efficiency language: fewer batch-release surprises, clearer chain of custody, cleaner audit trails, better documentation for MHRA-facing work and less rework during tech transfer.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Related directories
Frequently asked questions
How many Cell & Gene Therapy companies are there in the UK?
What counts as a Cell & Gene Therapy company in this list?
Which are the largest Cell & Gene Therapy companies in the UK?
What do Cell & Gene Therapy companies in the UK actually do?
How does UK Cell & Gene Therapy compare internationally?
How is this list built and how fresh is the data?
How big are the typical Cell & Gene Therapy companies in the UK?
Are these mostly new or established Cell & Gene Therapy companies?
What SIC codes does this use?
What buying signals should I look for?
Push these 66 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.